Dendritic Cell-Targeted LNP Development

Dendritic Cell-Targeted LNP Development

We develop dendritic cell-targeted LNPs through DC-selective lipid engineering and surface display of glycan, antibody, and single-domain antibody ligands, providing end-to-end support from lipid design and synthesis to formulation, characterization, and immune delivery evaluation.

Dendritic cell-targeted LNPs are engineered to direct nucleic acids, antigens, and immune modulators to dendritic cells (DCs)—the professional antigen-presenting cells that bridge innate sensing and adaptive immunity. A single DC can activate 100–200 naïve T cells, yet conventional ionizable LNPs deliver most of their payload to hepatocytes, leaving antigen-presenting cells with only a marginal share of the dose. DC-targeted formulations address this gap by combining DC-permissive ionizable lipids, tuned PEG-lipid architectures, and surface-displayed ligands—such as mannose, anti-DEC205, or anti-CLEC9A constructs—to shift particle uptake toward DCs, control the targeted DC subset, and shape the resulting Th1/Th2 immune bias.

BOC Sciences provides integrated targeted LNP development, covering DC-selective lipid screening, glycan and antibody ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo immune evaluation. We support customized LNPs for mRNA, siRNA, saRNA, circRNA, miRNA, ASO, CRISPR components, antigen proteins, and antigen–adjuvant co-delivery programs, with the targeting layer selected according to the intended DC subset and immune objective.

Schematic Diagram of Dendritic Cell-Targeted Lipid NanoparticlesDendritic Cell-Targeted Lipid Nanoparticle Illustration

BOC Sciences Dendritic Cell-Targeted LNP Development Services

Our development services combine lipid chemistry, ligand engineering, nanoparticle formulation, and immunological evaluation to address the specific challenges of dendritic cell delivery. Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a defined immune objective—such as raising a Th1-biased CD8+ T cell response or inducing tolerogenic DC signaling. We customize the development scope according to payload properties, target DC subset, and the intended administration route.

Dendritic Cell-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence DC association, endosomal handling, and immune organ distribution.

  • DC-Permissive Ionizable Lipid Selection: Compare lipid headgroups, ionization behavior, biodegradable linkers, and tail architecture to identify candidates that transfect DCs efficiently without relying on excessive cationic charge. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Anionic Phospholipid Balance: Adjust phospholipid identity—including anionic species such as DOPG and DOPE—cholesterol content, and PEG-lipid molar fraction, since these formulation-level variables govern albumin-associated lymphatic routing and DC uptake as much as the ionizable lipid itself.
  • Structure–Immune-Response Screening: Compare candidate lipid structures using particle attributes, DC transfection, maturation markers such as CD80 and CD86, and reporter expression to identify formulations that deliver functional payload rather than surface-bound signal.

DC-Targeting Ligand Engineering and Surface Functionalization

We develop ligand-functionalized LNPs to improve interactions with dendritic cells and selected DC subsets. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.

  • Glycan Ligand Design: Synthesize mannose, tri-mannose, fucose, and β-glucan-derived ligands conjugated to lipid anchors such as DSPE-PEG, matched to C-type lectin receptors including the mannose receptor (CD206), DC-SIGN, and Dectin family members.
  • Antibody, scFv, and Single-domain antibody display: Design antibody fragments and VHH domains directed toward DC-enriched receptors such as DEC205, CLEC9A, and XCR1, with receptor expression patterns and species specificity considered during ligand selection.
  • Conjugation and Surface Display: Optimize linker chemistry, lipid anchors, spacer length, ligand orientation, and surface density through appropriate nanoparticle conjugation services, while monitoring whether added ligands destabilize the particle or become masked by the protein corona.

Payload-Compatible LNP Formulation and Process Optimization

We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended immune application.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, mixing conditions, and formulation pH for different nucleic acid and protein payloads through customized lipid nanoparticle formulation.
  • Administration-Route and Lymphatic Adaptation: Compare formulation requirements for intramuscular, subcutaneous, intradermal, and intravenous administration, recognizing that lymphatic drainage, spleen filtration, and blood-borne distribution each favor different particle sizes and surface properties, as further described in our lymph node-targeted LNP development program.
  • PEG-Lipid and Ligand Balance: Adjust PEG-lipid content and ligand incorporation to balance colloidal stability with DC accessibility, supported by LNP PEG-lipid optimization services.
  • Process Parameter Optimization: Refine lipid concentration, mixing conditions, flow-rate ratios, and post-formulation processing through LNP process optimization.

Physicochemical, Cellular, and In Vivo Evaluation

We evaluate candidate LNPs at three levels—particle, cell, and organism—so that formulation changes can be interpreted against functional immune delivery rather than uptake alone.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • DC Uptake and Subset Resolution: Compare particle association and internalization in DC model lines, bone marrow-derived DCs, and human monocyte-derived DCs, resolving uptake by subset and lineage markers with nanoparticle cellular uptake testing.
  • Functional Delivery: Evaluate reporter expression, DC maturation phenotypes, antigen presentation, and target-gene knockdown according to the payload and research objective.
  • In Vivo Immune Delivery: Compare lymph node and spleen accumulation, the DC fraction among payload-positive cells, and off-target organ exposure, supported by nanoparticle cellular and in vivo evaluation.

Dendritic Cell-Targeting Strategies for Lipid Nanoparticles

DC-targeted LNPs can be developed through glycan-mediated receptor recognition, subset-specific antibody and single-domain antibody display, or ligand-free particle engineering in which size, PEG density, and surface charge enrich delivery to antigen-presenting cells. BOC Sciences supports ligand design and synthesis, lipid engineering, LNP formulation, and comparative evaluation. The following strategies provide different options for developing DC-targeted delivery systems.

Mannose- and Glycan-Functionalized LNPs for DC Targeting

Glycan-functionalized LNPs exploit C-type lectin receptors abundantly expressed on dendritic cells—most commonly the mannose receptor (CD206)—to promote receptor-mediated endocytosis and antigen presentation. BOC Sciences supports glycan ligand synthesis, lipid-anchor conjugation, glycan-density optimization, and LNP functionalization.

  • Design Approach: Conjugate mannose or oligomannose units to DSPE-PEG anchors with defined linker chemistry, then screen glycan density and PEG-lipid molar fraction together, since excessive PEG shielding can mask the glycan layer. Because CD206 is also expressed on macrophages, we pair glycan designs with uptake assays that distinguish DCs from phagocyte competitors.
  • Use Scenarios: Develop mannosylated mRNA-LNPs for cancer vaccine research, low-dose vaccination studies, and protein or peptide antigen delivery intended for enhanced MHC presentation.

Research reference: Mannosylated mRNA-LNPs (STLNPs-Man) achieving approximately four-fold higher DC uptake than benchmark LNPs and comparable antitumor efficacy at one-fifth of the vaccine dose (Angewandte Chemie International Edition, 2024).

CLEC9A- and DEC205-Targeted LNPs for DC Subsets

Antibody-fragment-functionalized LNPs direct particles to defined DC subsets—particularly type 1 conventional DCs (cDC1)—through receptors such as DEC205, CLEC9A, and XCR1. Because receptor choice influences the quality of the resulting immune response, we treat receptor selection as a design decision rather than a fixed default. BOC Sciences supports ligand selection, scFv and single-domain antibody production, conjugation chemistry, and functionalized LNP development.

  • Design Approach: Select receptors with experimentally confirmed expression on the intended subset, then design scFv, VHH, or chemically defined ligands accordingly. Optimize conjugation chemistry, spacer structure, ligand orientation, and surface density, using antibody conjugated lipid nanoparticles or VHH conjugated lipid nanoparticles formats as the project requires.
  • Use Scenarios: Develop cDC1-directed mRNA-LNPs for neoantigen vaccine research, siRNA-LNPs for silencing costimulatory genes such as CD40, CD80, and CD86 in DCs, and studies comparing immune output across DEC205-, CLEC9A-, and XCR1-targeted designs.

Research reference: DEC205-scFv-coated LNPs delivering siRNA to DCs with functional knockdown of CD40, CD80, and CD86 (Molecular Therapy, 2016); CLEC9A-binding single-domain antibody-functionalized LNPs enlarging mRNA-expressing DC populations and improving neoantigen-driven T cell responses (Vaccines, 2026); comparative receptor-targeting analysis showing that CLEC9A, XCR1, and DEC205 engagement produces distinct antibody and CD8+ T cell outcomes (The Journal of Immunology, 2020).

Size- and PEG-Engineered LNPs for DC Enrichment

DC enrichment does not always require an active ligand. Particle size, PEG-lipid density, and surface charge determine whether a formulation drains through lymphatics, filters into splenic antigen-presenting cell zones, or adsorbs the endogenous protein corona that routes particles to DCs. BOC Sciences supports formulation-level engineering and comparator design for ligand-free DC enrichment.

  • Design Approach: Tune particle diameter, reduce PEG-lipid content to low molar fractions, adjust helper phospholipid identity, and shift surface charge within ranges associated with splenic and lymph node delivery; larger low-PEG particles and anionic helper-lipid systems favor uptake by splenic DC populations after intravenous administration.
  • Use Scenarios: Develop ligand-free vaccine LNPs when ligand conjugation would complicate manufacturing or mask key surfaces, and build passive-targeting comparators against which active ligand designs are benchmarked.

Research reference: Stereodefined ionizable lipid H9T6 in a low-PEG, DOPG-containing formulation improving DC transfection and Th1-biased immune output after intramuscular vaccination (ACS Nano, 2026); large low-PEG LNPs achieving mRNA expression in roughly 82% of GFP+ splenic cells identified as DCs (Journal of Controlled Release, 2026).

Dual-Functional LNPs for Targeting and Endosomal Escape

DC uptake alone does not guarantee payload expression. mRNA that remains in endosomes is degraded rather than translated, so advanced DC-targeted designs combine surface targeting with pH-responsive or fusogenic components that accelerate endosomal release. BOC Sciences supports dual-functional lipid design, surface engineering, and comparative evaluation of targeting-only versus targeting-plus-escape formulations.

  • Design Approach: Combine glycan or antibody targeting with pH-responsive PEGylated lipids, fusogenic helper lipids, or charge-reversal components, and verify that each added function does not degrade particle stability or ligand accessibility. Relevant design options are described under pH-responsive lipid nanoparticles.
  • Use Scenarios: Develop mRNA vaccine LNPs requiring high antigen expression per particle, co-delivery programs pairing antigen-encoding RNA with adjuvant payloads for the same DC population, and formulations intended to strengthen CD8+ T cell priming.

Research reference: Ambidextrous LNPs combining mannose-directed DC targeting with pH-responsive endosomal escape, producing enhanced antigen translation and vigorous antitumor immune responses (mRNA cancer vaccine study, 2025).

Which DC-Targeting Strategy Fits Your LNP Project?

Share your payload, target DC subset, and immune objective. BOC Sciences can help evaluate feasible receptor and formulation options, synthesize relevant components, and develop a comparative screening strategy.

Supported Payloads for Dendritic Cell-Targeted LNPs

BOC Sciences develops DC-targeted LNPs for the payload classes most frequently used in dendritic cell delivery and vaccine research. Each payload imposes different requirements on loading strategy, particle stability, and functional readout, and we help connect the DC-targeting layer with payload-specific formulation demands.

Payload TypeSupported Uses & Dendritic Cell-Targeted LNP Development ConsiderationsRequest Information
DC-Targeted LNP for mRNAThe core payload for DC vaccine research, supporting neoantigen and model antigen expression, DC maturation, and T cell priming. Development focuses on mRNA integrity, DC-selective transfection, and lymph node versus liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
DC-Targeted LNP for saRNASelf-amplifying RNA supports low-dose vaccine concepts by intracellularly amplifying antigen expression. Development addresses the larger, structured RNA cargo with higher encapsulation demands, fusogenic helper lipid selection, and expression duration readouts in DC models, drawing on our lipid nanoparticles for saRNA delivery capabilities.Inquiry
DC-Targeted LNP for siRNAEnables functional gene silencing in DCs—for example, knockdown of costimulatory molecules such as CD40, CD80, and CD86 to study immune suppression or tolerance. Development evaluates oligonucleotide encapsulation, DC-selective uptake against macrophage competitors, and knockdown depth, building on our lipid nanoparticles for siRNA delivery experience.Inquiry
DC-Targeted LNP for circRNACircular RNA offers durable, cap-independent antigen expression of interest for prolonged antigen presentation studies. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in DC and lymph node contexts, supported by our lipid nanoparticles for circRNA delivery platform.Inquiry
DC-Targeted LNP for miRNASuitable for tuning DC differentiation and immune signaling pathways, including tolerogenic DC phenotypes studied in autoimmune research. Development evaluates miRNA loading, subset-resolved uptake, and pathway-level readouts, drawing on our lipid nanoparticles for miRNA delivery services.Inquiry
DC-Targeted LNP for ASOApplicable to splice-modifying and knockdown oligonucleotide research in immune cells, where nuclear delivery to DCs remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear accumulation, and uptake comparison across DC subsets, supported by our lipid nanoparticles for ASO delivery services.Inquiry
DC-Targeted LNP for Cas9 mRNA/sgRNA and CRISPR RNPEnables transient genome-editing studies in DCs and hematopoietic populations, where repeat dosing and short Cas9 exposure are advantageous. We evaluate co-loading of Cas9 mRNA with guide RNA or direct ribonucleoprotein loading, editing readouts in DC models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
DC-Targeted LNP for Antigen Protein and PeptideSupports direct antigen delivery for MHC loading and cross-presentation studies, including model antigens and tumor-derived peptide pools. Formulation work emphasizes mild loading conditions, preserved conformation, and DC uptake, drawing on our lipid nanoparticles for antigen delivery experience.Inquiry
DC-Targeted LNP for Antigen–Adjuvant Co-DeliveryDesigned so antigen and adjuvant arrive in the same DC at the same time—critical for TLR agonist-based, CpG-based, and STING-pathway programs. Development evaluates co-encapsulation compatibility, adjuvant distribution between particle compartments, and innate activation readouts, supported by our lipid nanoparticles for co-delivery capabilities.Inquiry
DC-Targeted LNP for Fluorescent and Tracking LabelsSupports labeled particles used to quantify the DC fraction among payload-positive cells, map lymph node versus spleen distribution, and validate whether ligand targeting survives the protein corona, enabled by our tracking-labeled lipid nanoparticles capabilities.Inquiry
DC-Targeted LNP for Custom PayloadDeveloped for unusual payloads, dual-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, DC-targeting modification route, particle stability, and delivery performance in the agreed DC models.Inquiry
Need a DC-Targeted LNP for Your Specific Payload?

Tell us your payload, target DC subset, and administration route, and BOC Sciences will propose a DC-targeting strategy that fits your project.

Our Dendritic Cell-Targeted LNP Development Workflow

Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and immune-delivery evidence becomes available.

Project requirement discussion

1Define the DC Subset, Target Receptor, and Payload

We review the payload class, the intended DC population—cDC1, cDC2, plasmacytoid DC, or migratory tissue DC—the desired immune outcome such as CD8+ T cell priming or tolerogenic signaling, baseline formulation if available, and the target administration route. These inputs define the receptor candidates, comparator models, and the screening plan.

Lipid composition and targeting architecture selection

2Select Lipid Composition and Targeting Architecture

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer—glycan display, antibody-fragment display, or ligand-free size and PEG engineering. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs so targeting effects can be attributed unambiguously.

LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention. We adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds and demonstrate preserved ligand accessibility after serum exposure.

Cellular and in vivo dendritic cell delivery evaluation

4Evaluate DC Uptake and Functional Payload Delivery

Selected candidates are evaluated in DC models using uptake imaging, flow cytometry with subset markers, and payload-specific endpoints such as reporter expression, maturation phenotype, or gene knockdown. In vivo studies then compare lymph node and spleen delivery against hepatic and macrophage-associated accumulation. In one recent mRNA neoantigen project, we screened twelve ionizable lipid candidates alongside three targeting architectures—mannosylated DSPE-PEG, anti-CLEC9A single-domain antibody display, and a ligand-free low-PEG design—against a common mRNA payload, and the single-domain antibody-functionalized formulation advanced with the highest DC fraction among payload-positive cells together with the strongest CD8+ T cell activation, while the low-PEG design was retained as a simpler manufacturing backup.

What Dendritic Cell-Targeted LNP Development Challenges Do We Solve?

A DC-targeted LNP may look well characterized chemically yet still deliver mostly to hepatocytes, macrophages, or the wrong DC subset—and uptake itself does not guarantee antigen presentation. We investigate formulation and immunological factors together and use matched comparison studies to identify the step limiting performance.

✔ Low Dendritic Cell Uptake by LNPs and Off-Target Phagocyte Capture

Conventional LNPs follow ApoE and LDL-receptor pathways into hepatocytes, while splenic macrophages and Kupffer cells capture much of the remainder before DCs see any dose. We compare ionizable lipid structures, PEG densities, helper lipid identities, and targeting ligands to shift uptake, and we quantify the DC fraction among payload-positive cells for every candidate rather than reporting total expression alone.

✔ Limited LNP Selectivity Across Dendritic Cell Subsets

Receptors widely used for DC targeting—such as the mannose receptor—are also expressed on macrophages and endothelial cells, and different receptors on the same cDC1 population produce different Th1/Th2 polarization and antibody isotype outcomes. We build subset-resolved flow cytometry readouts into each screening round, so receptor selection is made against measured DC subset engagement and immune bias data instead of receptor-list assumptions.

✔ Insufficient Endosomal Escape and Payload Expression from LNPs

DCs are notoriously difficult transfection targets, and internalized mRNA is frequently degraded in the endolysosomal pathway before translation. We measure ligand exposure alongside particle stability, compare intracellular localization with functional readouts, and apply LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.

✔ Uneven LNP Delivery to Lymph Nodes and Target Tissues

Lymphatic drainage after local injection and spleen filtration after intravenous administration each impose size- and surface-dependent filters, and the protein corona can redirect particles away from their intended receptor. We use labeled particles and compartment-aware readouts to map where payload expression actually occurs, then adjust particle size, PEG density, charge, and route-compatible design variables to reduce variability across the intended DC populations.

Facing Low DC Uptake or Poor Antigen Expression?

Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.

Applications of Dendritic Cell-Targeted LNPs

Dendritic cell-targeted LNPs provide a versatile approach for delivering antigen-encoding RNA, immunomodulatory oligonucleotides, and other research payloads to antigen-presenting cells. By combining cell-directed delivery with functional intracellular release, these systems can support research into cancer vaccines, antigen presentation, infectious disease immunity, and immune-regulatory gene modulation. BOC Sciences develops customized LNP formulations according to the intended immune response and payload requirements.

01

mRNA Cancer Vaccines and Neoantigen Delivery

  • Tumor-Associated Antigen Expression: Develop DC-targeted mRNA-LNPs encoding selected tumor-associated antigens or neoantigens to investigate antigen expression, processing, and presentation by DC populations. CLEC9A-directed LNP research has demonstrated enhanced delivery of neoantigen-encoding mRNA to DCs and investigated downstream antigen-specific T-cell responses (Vaccines, 2026).
  • cDC1-Associated Antigen Cross-Presentation: Explore receptor-directed and composition-engineered LNPs for antigen delivery to cDC1 populations, with evaluation of antigen presentation through MHC class I and subsequent CD8+ T-cell activation. Large, low-PEG LNP formulations have also been investigated for enhanced DC transfection and antigen presentation (Journal of Controlled Release, 2026).
02

Antigen and Adjuvant Co-Delivery for DC Activation

  • Coordinated Antigen and Adjuvant Delivery: Develop LNPs that combine antigen-encoding mRNA with immunostimulatory oligonucleotides, such as CpG-containing sequences, to investigate coordinated delivery to antigen-presenting cells. Lipid-anchored CpG and mRNA-LNP systems have been studied for improving lymphoid-tissue adjuvant delivery and DC-associated cross-priming (Journal of Nanobiotechnology, 2026).
  • DC Maturation and Antigen Presentation: Evaluate the expression of costimulatory markers such as CD40, CD80, and CD86, together with antigen presentation, cytokine responses, and antigen-specific T-cell activation. Lipid composition and helper lipid screening can also influence DC maturation and immune activation profiles (Nature Biomedical Engineering, 2024).
03

Antiviral and Infectious Disease Vaccine Research

  • Viral Antigen Expression: Develop mRNA-LNPs encoding selected viral antigens to investigate antigen production and presentation by DCs. Formulation strategies can incorporate receptor-directed targeting or glycolipid-based surface engineering to improve interactions with antigen-presenting cells.
  • Cellular and Humoral Immune Responses: Explore LNP formulations that coordinate antigen expression and immune stimulation, then evaluate DC maturation, cytokine production, antigen-specific T-cell responses, and antibody-associated immune readouts. Glycolipid-stabilized mRNA nanovaccine research has demonstrated enhanced DC uptake and immune responses following in vivo administration (Advanced Functional Materials, 2026). These findings provide a research basis for further DC-directed lipid nanoparticle vaccine development.
04

siRNA Delivery for DC Gene Silencing and Immune Modulation

  • Costimulatory Molecule Regulation: Develop receptor-directed siRNA-LNPs to investigate the knockdown of DC-associated costimulatory molecules, including CD40, CD80, and CD86. DEC205-functionalized LNP research has demonstrated preferential siRNA delivery to DEC205-positive DCs and functional suppression of selected costimulatory signals (Molecular Therapy, 2016).
  • Immune-Regulatory Gene Silencing: Explore siRNA delivery against selected inhibitory or immune-regulatory targets, such as PD-L1, to investigate changes in DC-T-cell interactions. A 2026 DC-targeted LNP study investigated the co-delivery of antigen-encoding RNA and PD-L1-targeting siRNA to coordinate antigen presentation and gene silencing (Advanced Materials, 2026).
Develop a Dendritic Cell-Targeted LNP for Your Research Application

Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate DC-targeted LNPs tailored to your project.

Why Choose BOC Sciences for Dendritic Cell-Targeted LNP Development?

Dendritic Cell-Directed Lipid and Ligand Design Expertise

We connect ionizable lipid structure, PEG architecture, and receptor choice to DC subset engagement and immune bias, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

Specialized Lipid Materials and Targeting Ligands

Our workflows cover glycan ligands, scFv and VHH constructs, peptide motifs, and ligand-free particle engineering, allowing the targeting layer to be matched to the DC subset and immune objective rather than forced onto a fixed platform.

Comprehensive In Vitro and In Vivo Evaluation

Particle profiling, subset-resolved DC uptake, endosomal escape assessment, and in vivo lymph node and spleen distribution studies are combined in one program, so formulation changes can be interpreted against both cellular and tissue-level delivery data.

Comparative Screening and Iterative Formulation Optimization

Screening campaigns are organized around parallel candidate comparison with matched non-targeted controls and agreed endpoints, giving teams fast, interpretable feedback on which design variable to adjust in the next iteration.

End-to-End Dendritic Cell-Targeted LNP Development Services

From ligand selection and lipid synthesis to formulation, characterization, and immune delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and particle performance.

FAQs

What are dendritic cell-targeted lipid nanoparticles?

Dendritic cell-targeted lipid nanoparticles (DC-targeted LNPs) are lipid-based delivery systems engineered to transport nucleic acids and other functional payloads into dendritic cells (DCs). These nanoparticles can be modified with receptor-binding ligands, such as mannose or antibody-based components, or optimized through lipid composition and particle-size engineering to improve DC uptake. Their applications include antigen expression, immune modulation, and gene silencing research. Unlike conventional LNPs, which may accumulate in the liver or other phagocytic cells, DC-targeted formulations aim to improve delivery to selected antigen-presenting cell populations and support functional intracellular payload release.

DC-targeted LNPs can be engineered through surface functionalization and lipid composition optimization. Mannose-bearing lipids can facilitate recognition by CD206-positive cells, while antibodies or engineered protein binders directed toward CLEC9A and DEC205 can support receptor-mediated delivery to selected DC populations. Particle size, PEG-lipid content, and ionizable lipid structure can also be adjusted to influence cellular uptake and tissue distribution. BOC Sciences supports these approaches through customized lipid design, targeting ligand synthesis, surface conjugation, LNP formulation, and comparative cellular evaluation. The optimal design depends on receptor expression, target DC subsets, payload properties, and administration route.

Several receptors can be explored for dendritic cell-targeted LNP development. CD206, also known as the mannose receptor, recognizes mannose-containing structures and can facilitate uptake by selected antigen-presenting cells, although it is also expressed by macrophages. CLEC9A is particularly relevant to cDC1 targeting and antigen cross-presentation, whereas DEC205 is an endocytic receptor investigated for DC-directed antigen and siRNA delivery. Receptor selection should consider cell-subset expression, species compatibility, and ligand accessibility. BOC Sciences can help evaluate receptor-binding components and compare their uptake profiles across DC populations and other immune-cell types.

DC-targeted LNPs can deliver several types of research payloads, particularly mRNA and siRNA. Antigen-encoding mRNA can support intracellular expression of tumor-associated antigens, neoantigens, or viral antigens for antigen-presentation research. siRNA can be used to investigate gene silencing involving costimulatory or immune-regulatory pathways. Co-delivery strategies may combine antigen-encoding mRNA with siRNA or immunostimulatory oligonucleotides to investigate coordinated antigen expression and immune modulation. BOC Sciences develops payload-compatible formulations by optimizing encapsulation conditions, lipid-to-payload ratios, particle composition, and intracellular release according to the intended DC application.

Functional delivery evaluation combines nanoparticle characterization, cell-specific uptake analysis, intracellular trafficking, and biological readouts. Initial characterization includes particle size, polydispersity index, zeta potential, morphology, and encapsulation efficiency. Cellular studies compare LNP uptake across selected DC subsets, including cDC1 and cDC2, with macrophages and other immune cells serving as relevant comparators. Further evaluation can include endosomal escape, reporter expression, target-gene knockdown, DC maturation markers, cytokine production, and antigen presentation. For selected projects, studies can assess lymph node and spleen distribution, DC localization, and off-target organ accumulation to determine whether particle uptake translates into functional delivery.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code